Top in endocrinology: AI in diabetes care; safety of tirzepatide
Click Here to Manage Email Alerts
Artificial intelligence may allow health care providers to combine large data sources to identify and calculate likely outcomes for individual patients, which may prove helpful in diabetes care, according to experts.
“The idea is that the information is so detailed and you have access to so many patients in your large database that you can make a good prediction of what’s going to happen next,” David C. Klonoff, MD, FACP, FRCP (Edin), Fellow AIMBE, a clinical professor of medicine at the University of California, San Francisco, and medical director of the Diabetes Research Institute at Mills-Peninsula Medical Center, told Healio.
It was the top story in endocrinology last week.
The second top story covered data on tirzepatide (Mounjaro, Eli Lilly) that showed gastrointestinal adverse events were common, but less than 10% of adults receiving the medication reported a serious adverse event.
Read these and more top stories in endocrinology below:
'The more data ... the better': AI poised to alter diabetes care
Artificial intelligence is not yet a routine fixture in medicine, but it may soon change how physicians approach medical care, including prediction and diagnosis of diabetes complications. Read more.
Serious adverse events rare among adults receiving tirzepatide in clinical trials
More than one-third of adults receiving tirzepatide in clinical trials experience gastrointestinal adverse events, but adverse events leading to drug discontinuation were rare, according to study data. Read more.
FDA expands teprotumumab indication to include any thyroid eye disease duration, activity
The FDA approved expanded indication language to allow the use of teprotumumab for the treatment of thyroid eye disease for any level of activity or duration, according to a press release. Read more.
Insulin degludec noninferior to insulin detemir for pregnant women with type 1 diabetes
Pregnant women with type 1 diabetes who were treated with insulin degludec had a similar reduction in HbA1c as those using insulin detemir, according to findings published in The Lancet Diabetes & Endocrinology. Read more.
Testosterone therapy may benefit men with diabetes and obesity, but remains controversial
An increasing number of studies are reporting that testosterone therapy may not only normalize testosterone levels for men but may also provide cardiometabolic benefits. Read more.